Summary
The REGULATE-PCI trial compared REG1, a novel factor IXa inhibitor system for patients undergoing percutaneous coronary intervention, with bivalirudin for safety and efficacy outcomes. After just under a year of data collection, an unexpected increase in severe allergic reaction to the REG1 system led to early termination of the trial.
- REGULATE-PCI
- REG1 anticoagulation system
- percutaneous coronary intervention
- antithrombotic therapy
- bivalirudin
- bleeding outcomes
- stent thrombosis
- cardiology & cardiovascular medicine clinical trials
- NCT01848106
- © 2015 SAGE Publications